)
Edge15 May 2026
TOMRA: Closing the Loop
The story of TOMRA: from reverse vending machine pioneer to global technology for deposit systems, recycling, and resource optimization.
Mainz Biomed
Mainz Biomed (QUCY) investor relations material
Mainz Biomed Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 earnings summary15 May, 2026
Executive summary
Strategic shift to focus on pancreatic cancer screening and post-quantum cybersecurity, exiting colorectal cancer business with asset sales completed in March and April 2026.
Leadership changes included appointing a new non-executive Chairman and CEO to align with the new business direction.
Company rebranded to Quantum Cyber N.V. and changed its NASDAQ ticker to QUCY.
Financial highlights
Net loss from continuing operations was $2.5 million for Q1 2026, down 10% year-over-year.
Net loss from discontinued operations was $2.6 million, up 16% year-over-year.
Total net loss for Q1 2026 was $5.1 million, a 2% increase from Q1 2025.
Cash and cash equivalents at March 31, 2026 were $4.75 million, up from $0.89 million at year-end 2025.
Operating cash outflows improved to $2.7 million from $3.9 million year-over-year.
Outlook and guidance
Focus on commercializing blood-based pancreatic cancer screening and expanding into post-quantum cybersecurity.
Management expects current cash and planned financing to cover expenditures for at least one year, but substantial doubt remains about long-term viability.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Mainz Biomed
- 2025 saw a strategic pivot to pancreatic cancer diagnostics, a 40% revenue drop, and a $16.2M net loss.QUCY
H2 202531 Mar 2026 - Approval of all proposals enables a $6M investment, board overhaul, and recapitalization.QUCYProxy filing25 Mar 2026
- Shareholders will vote on a $6M investment, board overhaul, and major capital structure changes.QUCYProxy Filing12 Mar 2026
- Offering up to $150M in securities to advance innovative cancer diagnostics amid high risk.QUCYRegistration Filing16 Dec 2025
- Up to 4.59 million shares and units are offered, with Maxim Group LLC as placement agent.QUCYRegistration Filing30 Nov 2025
- IPO aims to fund CRC diagnostics growth amid financial risk and Nasdaq compliance challenges.QUCYRegistration Filing29 Nov 2025
- Best-efforts offering seeks $5.33M for cancer diagnostics R&D and expansion, with high investor risk.QUCYRegistration Filing29 Nov 2025
- Offering up to $7.1M net to fund CRC diagnostics expansion, with high dilution and Nasdaq risks.QUCYRegistration Filing29 Nov 2025
- Raising up to $6M for cancer diagnostics, with high risk, dilution, and strong market potential.QUCYRegistration Filing29 Nov 2025
Next Mainz Biomed earnings date
H1 202614 Aug, 2026
Mainz Biomed
Next Mainz Biomed earnings date
H1 202614 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage